Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Posts Earnings Results, Beats Estimates By $0.09 EPS

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) issued its quarterly earnings data on Tuesday. The company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.09, Yahoo Finance reports. The firm had revenue of $52.36 million during the quarter, compared to analysts’ expectations of $42.89 million. Calliditas Therapeutics AB (publ) had a negative net margin of 40.19% and a negative return on equity of 160.87%. During the same period last year, the company earned ($0.33) earnings per share.

Calliditas Therapeutics AB (publ) Price Performance

NASDAQ:CALT traded up $0.27 during mid-day trading on Wednesday, hitting $39.51. 4,307 shares of the stock traded hands, compared to its average volume of 10,019. The business’s 50-day moving average price is $39.01 and its 200 day moving average price is $28.10. The company has a market cap of $1.18 billion, a PE ratio of -21.22 and a beta of 1.77. Calliditas Therapeutics AB has a 12-month low of $15.25 and a 12-month high of $41.90. The company has a quick ratio of 2.62, a current ratio of 2.69 and a debt-to-equity ratio of 8.46.

Analysts Set New Price Targets

CALT has been the topic of several analyst reports. Stifel Nicolaus restated a “hold” rating and set a $40.00 price target (down from $55.00) on shares of Calliditas Therapeutics AB (publ) in a report on Tuesday, May 28th. HC Wainwright reaffirmed a “neutral” rating and issued a $39.00 price objective on shares of Calliditas Therapeutics AB (publ) in a research report on Tuesday, May 28th. Lifesci Capital lowered shares of Calliditas Therapeutics AB (publ) from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, May 28th. Jefferies Financial Group reissued a “hold” rating and issued a $39.00 price target (down previously from $58.00) on shares of Calliditas Therapeutics AB (publ) in a research report on Tuesday, May 28th. Finally, Citigroup reissued a “neutral” rating and issued a $39.00 price target on shares of Calliditas Therapeutics AB (publ) in a research report on Friday, May 31st. Six research analysts have rated the stock with a hold rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $35.00.

About Calliditas Therapeutics AB (publ)

Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia.